Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Taxadrol is a natural testosterone-boosting nutraceutical developed by Dr. Jeff Golini and manufactured by All American Pharmaceutical. It is a non-prohormone, non-steroidal supplement derived from a proprietary whole-plant extract of a specific Montana pine species (*Pinus silvestris*). The extract contains a complex mixture of flavonoids, terpenoids, and phytosterols. Taxadrol's biological mechanism involves stimulating the body's endogenous production of testosterone and increasing free testosterone levels while simultaneously functioning as an anti-aromatase agent to inhibit the conversion of testosterone into estrogen. It is primarily indicated for sports nutrition and athletic performance enhancement, targeting muscle building, strength increases, and the management of testosterone deficiency in athletes and older men. Preclinical and human case studies have demonstrated significant increases in testosterone levels without reported toxicity or major side effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Taxadrol.